← Back to all trials
Not Yet Recruiting
NCT07784478
Effect of Oxytocin Bolus Versus Slow Infusion on Haemodynamic Stability During Caesarean Section Under Spinal Anaesthesia
Conditions: Cesarean Section, Hypotension, Postpartum Hemorrhage, Spinal Anesthesia
Sex: Female
Ages: 18 Years – 40 Years
Healthy volunteers: No
Phase: NA
Enrollment: 60
Sponsor: Khyber Girls Medical College
Location: Hayatabad Medical Complex / Khyber Girls Medical College Peshawar Khyber Pakhtunkhwa
Summary
This study compares two standard ways of giving oxytocin (a medicine that helps the uterus contract) after the baby is born during a planned caesarean section performed under spinal anaesthesia. One group of women will receive oxytocin as a quick injection into the vein. The other group will receive the same dose of oxytocin as a slow infusion over 15 minutes. The researchers want to find out which method causes less drop in blood pressure and other heart-related changes, while still providing good contraction of the uterus and preventing excessive bleeding.
Eligibility Criteria
Inclusion Criteria:
* Adult female patients aged 18 to 40 years
* American Society of Anesthesiologists (ASA) physical status class I or II
* Singleton pregnancy at 37 to 42 weeks gestational age
* Scheduled for elective caesarean section under spinal anaesthesia
* Written informed consent obtained
Exclusion Criteria:
* Patients with anticipated hemodynamic instability including severe preeclampsia/eclampsia, placenta previa with active bleeding, placental abruption, or hemorrhagic shock
* Pre-existing cardiovascular disease including ischemic heart disease, valvular heart disease, cardiomyopathy, or arrhythmias
* Baseline systolic blood pressure \< 100 mmHg or heart rate \> 100 bpm before spinal block
* Known hypersensitivity to oxytocin
* Failed spinal anaesthesia requiring conversion to general anaesthesia
* Patients receiving medications that may alter the hemodynamic response to oxytocin (beta-blockers, calcium channel blockers, ACE inhibitors, or angiotensin receptor blockers)
* Pre-existing anaemia (Hb \< 8 g/dL)
Source: ClinicalTrials.gov (NCT07784478). StuddyBuddy aggregates publicly available trial information.